XPO1 and acute myeloid leukemia: XPO1 inhibitors inhibit the nuclear export translation process of BCL2 and MCL1 mRNA mediated by eIF4E (eukaryotic initiation factor 4E), simultaneously downregulate the expression of BCL2 and MCL1 proteins, and induce apoptosis in AML cells (Fischer et al., 2020; Luedtke et al., 2018).